Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 5/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.65 |
| ▸ | GAA | P10253 | 2/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | VCP | P55072 | 7/20 | 0.64 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16409978 | 0.88 | SIRT2 (1.00) | SIRT2NPSR1GAAMEN1KMT2A | |
| SCHEMBL16409979 | 0.84 | SIRT2 (0.73) | SIRT2NPSR1GAAMEN1KMT2A | |
| SCHEMBL28043757 | 0.83 | SIRT2 (0.71) | SIRT2NPSR1GAAMEN1KMT2A | |
| SCHEMBL28043513 | 0.81 | SIRT2 (0.84) | SIRT2NPSR1GAAMEN1KMT2A | |
| SCHEMBL28043510 | 0.81 | SIRT2 (0.71) | SIRT2NPSR1GAAMEN1KMT2A | |
| SCHEMBL31160437 | 0.78 | SIRT2 (0.64) | SIRT2NPSR1GAAMEN1KMT2A | |
| SCHEMBL28043514 | 0.78 | SIRT2 (0.80) | SIRT2NPSR1GAAMEN1KMT2A | |
| SCHEMBL16409996 | 0.76 | SIRT2 (1.00) | SIRT2NPSR1GAAMEN1KMT2A | |
| SCHEMBL6404280 | 0.76 | SIRT2 (0.72) | SIRT2NPSR1GAAMEN1KMT2A | |
| SCHEMBL31160391 | 0.75 | SIRT2 (0.60) | SIRT2NPSR1GAAPTK2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9737525-B2 | Small molecule activators of NRF2 pathway | THE GENERAL HOSPITAL CORPORATION (US) | 2017-08-22 | — | — | US | disclosed |
| US-9737525-B2 | Small molecule activators of NRF2 pathway | THE GENERAL HOSPITAL CORPORATION (US) | 2017-08-22 | — | — | US | disclosed |
| US-20160101098-A1 | SMALL MOLECULE ACTIVATORS OF NRF2 PATHWAY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-04-14 | — | — | US | disclosed |
| US-20160101098-A1 | SMALL MOLECULE ACTIVATORS OF NRF2 PATHWAY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160101098-A1 | SMALL MOLECULE ACTIVATORS OF NRF2 PATHWAY | KEAP1, NFE2L2, GSTK1 | SIRT2 287/4885NPSR1 3007/4885GAA 1134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.